Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Clin Psychiatry ; 71(4): 400-10, 2010 Apr.
Article in English | MEDLINE | ID: mdl-19925748

ABSTRACT

OBJECTIVE: This study provides national data on medication access and continuity problems experienced during the first year of the Medicare Part D prescription drug program, which was implemented on January 1, 2006, among a national sample of Medicare and Medicaid "dual eligible" psychiatric patients. METHOD: Practice-based research methods were used to collect clinician-reported data across the full range of public and private psychiatric treatment settings. A random sample of psychiatrists was selected from the American Medical Association Physician Masterfile. Among these physicians, 1,490 provided clinically detailed data on a systematically selected sample of 2,941 dual eligible psychiatric patients. RESULTS: Overall, 43.3% of patients were reported to be unable to obtain clinically indicated medication refills or new prescriptions in 2006 because they were not covered or approved; 28.9% discontinued or temporarily stopped their medication(s) as a result of prescription drug coverage or management issues; and 27.7% were reported to be previously stable on their medications but were required to switch medications. Adjusting for case mix to control for sociodemographic and clinical confounders, the predicted probability of an adverse event among patients with medication access problems was 0.64 compared to 0.36 for those without access problems (P < .0001). All prescription drug utilization management features studied were associated with increased medication access problems (P < .0001). Adjusting for patient case mix, patients with "step therapy" (P < .0001), limits on medication number/dosing (P < .0001), or prior authorization (P < .0001) had 2.4 to 3.4 times the increased likelihood of an adverse event. CONCLUSIONS: More effective Part D policies and management practices are needed to promote clinically safer and appropriate pharmacotherapy for psychiatric patients to enhance treatment outcomes.


Subject(s)
Continuity of Patient Care/standards , Health Services Accessibility/standards , Medicaid/standards , Medicare Part D/standards , Mental Disorders/drug therapy , Prescription Drugs/therapeutic use , Psychotropic Drugs/therapeutic use , Adult , Aged , Diagnosis-Related Groups/standards , Drug Costs/statistics & numerical data , Female , Humans , Insurance Coverage/standards , Insurance, Pharmaceutical Services/standards , Male , Medicaid/economics , Medicare/economics , Medicare/legislation & jurisprudence , Medicare/standards , Medicare Part D/economics , Medication Therapy Management/standards , Mental Disorders/psychology , Middle Aged , Practice Patterns, Physicians'/standards , Practice Patterns, Physicians'/statistics & numerical data , Prescription Drugs/economics , Prescription Drugs/standards , Psychiatry/standards , Psychiatry/statistics & numerical data , Psychotropic Drugs/economics , Surveys and Questionnaires , United States
2.
Am J Psychiatry ; 164(5): 789-96, 2007 May.
Article in English | MEDLINE | ID: mdl-17475738

ABSTRACT

OBJECTIVE: This study attempted to systematically assess the experiences of Medicare and Medicaid "dual-eligible" psychiatric patients, including evaluating patients' access to medications and the administrative functioning of the program, during the first 4 months of the Medicare Part D prescription drug benefit. METHOD: Psychiatrists (N=5,833) were randomly selected from the American Medical Association's Physicians Masterfile. After exclusion of those not practicing and with undeliverable addresses, 64% responded; 35% met study eligibility criteria of treating at least one dual-eligible patient during their last typical workweek and reported clinically detailed information on one systematically selected patient. RESULTS: A total of 53.4% had at least one medication access problem to report between Jan. 1 and April 30, 2006. Although 9.7% experienced improved medication access, 22.3% discontinued or temporarily stopped taking medication because of prescription drug coverage or management issues, and 18.3% were previously stable but were required to switch medications. Among those with medication access problems, 27.3% experienced a significant adverse clinical event; 19.8% had an emergency room visit. Most drug plan features studied, including preferred drug/formulary lists, prior authorization, medication dosing/number limits, "fail-first" protocols, and requirements to switch to generics, were associated with significantly higher rates of medication access problems. CONCLUSIONS: The findings indicate consequential medication access problems for psychiatric patients during the implementation of Medicare Part D. Although Centers for Medicare and Medicaid Services policies were enacted to ensure access to protected classes of psychopharmacologic medications, the high rates of medication access problems observed indicate further refinement of these policies is needed.


Subject(s)
Continuity of Patient Care/standards , Health Services Accessibility , Insurance Benefits/standards , Insurance, Pharmaceutical Services/standards , Medicaid/legislation & jurisprudence , Medicare/legislation & jurisprudence , Mental Disorders/drug therapy , Adult , Aged , Delivery of Health Care/organization & administration , Delivery of Health Care/standards , Drug Costs , Drug Prescriptions/statistics & numerical data , Female , Health Care Surveys , Health Policy/legislation & jurisprudence , Humans , Insurance Benefits/legislation & jurisprudence , Insurance, Pharmaceutical Services/legislation & jurisprudence , Male , Medicaid/standards , Medicare/standards , Middle Aged , Polypharmacy , Psychotropic Drugs/economics , Psychotropic Drugs/therapeutic use , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...